Key result
Antiplatelet agents like aspirin and ticlopidine, along with oral anticoagulants, have established roles in the primary and secondary prevention of arterial thromboembolism across various conditions.
Why the study?
Do antithrombotic therapies prevent arterial thromboembolism in patients at risk for primary and secondary cardiovascular events?
Do antithrombotic therapies prevent arterial thromboembolism in patients at risk for primary and secondary cardiovascular events?
This review outlines the established roles of antiplatelet and anticoagulant therapies in preventing arterial thromboembolism across a wide spectrum of cardiovascular and cerebrovascular diseases.
No takes yet. Share an insight, caveat, or question.
Supports established antithrombotic prevention; leaves open optimization with newer agents in contemporary cohorts.
M Verstraete (1994) conducted a review in Arterial thromboembolism. Antiplatelet and anticoagulant therapies was evaluated. Antiplatelet agents like aspirin and ticlopidine, along with oral anticoagulants, have established roles in the primary and secondary prevention of arterial thromboembolism across various conditions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: